[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 42 of about 42
1. Naseem S, Gupta R, Kashyap R, Nityanand S: T-cell prolymphocytic leukemia: a report of two cases with review of literature. Indian J Hematol Blood Transfus; 2008 Dec;24(4):178-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell prolymphocytic leukemia: a report of two cases with review of literature.
  • T-cell Prolymphocytic Leukemia (T-PLL) is a mature post-thymic T-cell malignancy with aggressive clinical course.
  • The principal disease characteristics are organomegaly, skin lesions and raised lymphocyte counts.
  • T-PLL is a rare T-cell malignancy with characteristic clinical and laboratory features and a poor prognosis.
  • It needs to be differentiated from B-Cell prolymphocytic leukemia (B-PLL) and other mature T-cell lymphoproliferative disorders with predominant leukemic pattern.
  • Differentiation can be made by a comprehensive approach taking into account the clinical features, the cell morphology and the immunophenotype of leukemic cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Leukemia. 1990 Apr;4(4):262-6 [2366582.001]
  • [Cites] Blood. 1987 Oct;70(4):926-31 [3115337.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Br J Haematol. 1980 Jul;45(3):513-4 [6968583.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):525-36 [15325197.001]
  • [Cites] Lancet. 1973 Aug 4;2(7823):232-4 [4124423.001]
  • (PMID = 23100959.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3475431
  • [Keywords] NOTNLM ; Immunophenotyping / Prolymphocyte / T-PLL
  •  go-up   go-down


2. Mikaelsson E, Danesh-Manesh AH, Lüppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, Mellstedt H, Rabbani H: Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood; 2005 Jun 15;105(12):4828-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.
  • Fibromodulin is an extracellular matrix protein normally produced by collagen-rich tissues; the fibromodulin gene has been found to be the most overexpressed gene in B-cell chronic lymphocytic leukemia.
  • In this study, fibromodulin was expressed at the gene level (reverse transcription-polymerase chain reaction [RT-PCR]) in all patients with B-CLL (n = 75) and in most (5 of 7) patients with mantle cell lymphoma (MCL).
  • Fibromodulin was also detected at the protein level in the cytoplasm of the B-CLL cells and in the supernatant after in vitro cultivation, but not at the cell surface.
  • Fibromodulin was not found in patients with T-cell chronic lymphocytic leukemia (T-CLL), B-cell prolymphocytic leukemia (B-PLL), T-cell prolymphocytic leukemia (T-PLL), hairy cell leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, multiple myeloma, acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), or chronic myelogenous leukemia (CML) or in 36 hematologic cell lines.
  • [MeSH-major] Extracellular Matrix / metabolism. Extracellular Matrix Proteins / chemistry. Gene Expression Regulation, Neoplastic. Leukemia, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, Mantle-Cell / metabolism. Proteoglycans / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / biosynthesis. Antigens, CD19 / biosynthesis. Antigens, CD5 / biosynthesis. Antigens, Differentiation, T-Lymphocyte / biosynthesis. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line, Transformed. Cell Line, Tumor. Coculture Techniques. Collagen / metabolism. Cytoplasm / metabolism. DNA Mutational Analysis. DNA, Complementary / metabolism. Female. Fibroblasts / metabolism. Flow Cytometry. Hematologic Neoplasms / metabolism. Humans. Immunoblotting. Lectins, C-Type. Leukemia, T-Cell / metabolism. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Mutation. Palatine Tonsil / metabolism. RNA, Messenger / metabolism. Receptors, Interleukin-2 / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tetradecanoylphorbol Acetate / pharmacology. Time Factors

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15741214.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / CD69 antigen; 0 / DNA, Complementary; 0 / Extracellular Matrix Proteins; 0 / Lectins, C-Type; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / Receptors, Interleukin-2; 126468-95-9 / fibromodulin; 9007-34-5 / Collagen; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


3. Jeong KH, Lew BL, Sim WY: Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis. Acta Derm Venereol; 2009;89(5):509-12
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generalized leukaemia cutis from a small cell variant of T-cell prolymphocytic leukaemia presenting with exfoliative dermatitis.
  • T-cell prolymphocytic leukaemia (T-PLL) is a rare, aggressive neoplasm of mature T lymphocytes.
  • The small cell variant occurs in approximately 20% of T-PLL patients.
  • The skin findings of leukaemia consist of leukaemia-specific skin lesions, which are infiltrated by leukaemia cells, and non-specific lesions.
  • The former type of lesion signifies leukaemia cutis.
  • Leukaemia cutis presents clinically as tumours, nodules, or patches on the scalp, face and trunk.
  • We suspected a hidden malignancy and diagnosed small cell variant T-PLL through blood and bone marrow examination.
  • Most of the atypical lymphocytes stained positively with CD markers such as CD2, CD3, CD4, CD5, CD7 and CD8, thereby confirming the presence of leukaemia cells.
  • To our knowledge, this is the first case of generalized leukaemia cutis from small cell variant of T-PLL presenting with exfoliative dermatitis over the whole body.
  • [MeSH-major] Dermatitis, Exfoliative / etiology. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemic Infiltration. Skin / pathology. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Exfoliative Dermatitis.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734979.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone
  •  go-up   go-down


Advertisement
4. Nakashima H, Saito B, Ariizumi H, Matsuda I, Nakamaki T, Tomoyasu S: [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia]. Rinsho Ketsueki; 2008 Dec;49(12):1619-22
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic irradiation as a successful treatment for an elderly patient with B-cell prolymphocytic leukemia].
  • We report a case of B-cell prolymphocytic leukemia (B-PLL) that was treated successfully with splenic irradiation (SI).
  • Peripheral blood showed hemoglobin level 9.8 g/dl and white blood cell count 38.1x10(9)/l with 91% atypical cells.
  • A diagnosis of B-PLL was made.
  • [MeSH-major] Leukemia, Prolymphocytic, B-Cell / radiotherapy. Spleen

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110524.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


5. Wanko SO, de Castro C: Hairy cell leukemia: an elusive but treatable disease. Oncologist; 2006 Jul-Aug;11(7):780-9
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hairy cell leukemia: an elusive but treatable disease.
  • Hairy cell leukemia (HCL) is a unique chronic lymphoproliferative disorder that can mimic or coexist with other clonal hematologic disorders and has been associated with autoimmune disorders.
  • It should be entertained as an alternative diagnosis in patients with cytopenias being assigned the diagnosis of aplastic anemia, hypoplastic myelodysplastic syndrome, atypical chronic lymphocytic leukemia, B-prolymphocytic leukemia, or idiopathic myelofibrosis.
  • The typical presentation is that of a middle-aged man with an incidental finding of pancytopenia, splenomegaly, and inaspirable bone marrow.
  • Relapsed disease after a prolonged remission can often be successfully retreated with the same initial agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / pathology. Leukemia, Hairy Cell / therapy

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16880237.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab; 9008-11-1 / Interferons
  •  go-up   go-down


6. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Cavalcanti Júnior GB, Sales VS, Cavalcanti e Silva DG, Lopes MC, Paiva Ade S, da Fonseca HE, do Nascimento Júniors FF, Fernandes MZ: Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia. Acta Cir Bras; 2005;20 Suppl 1:101-7
Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of CD5 in B-cell chronic lymphoproliferative diseases by flow cytometry: a strong expression in B-cell chronic lymphocytic leukemia.
  • PURPOSE: CD5 is a T cell marker, aberrantly express in B cell chronic lymphocytic leukemia (B-CLL) and mantle cell lymphoma (MCL).
  • Other chronic B cell malignancies including hairy cell leukemia (HCL) and B cell prolymphocytic leukemia (B-PLL) are CD5 negative or express this antigen in a weak way.
  • In this study, CD5 expression was investigated in leukemic cells from 42 patients with chronic B cell lymphoproliferative disease.
  • METHODS: We studied the CD5 expression in leukemic cells from 42 patients with chronic B-cell malignancies by flow cytometry.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16186976.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Crisostomo RH, Fernandez JA, Caceres W: Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia. Leuk Res; 2007 May;31(5):699-701
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex karyotype including chromosomal translocation (8;14) (q24;q32) in one case with B-cell prolymphocytic leukemia.
  • We report a case of a 64-year-old white female patient, who presented with symptomatic anemia (Hgb: 6.8g/dl), thrombocytopenia (platelets: 94,000/mcl) and leukocytosis (WBC: 156,000/mcl).
  • Peripheral blood smear revealed markedly increased white blood cell count with predominance of atypical lymphoid cells of intermediate size, moderately dense chromatin, and prominent large single nucleoli.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 8. Leukemia, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997373.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


9. Telek B, Batár P, Rejto L, Udvardy M: [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol]. Orv Hetil; 2010 Aug 1;151(31):1261-3
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol].
  • [Transliterated title] B-sejtes prolymphocytás leukaemia (B-PLL) sikeres kezelése FCR-Lite (fludarabin, cyclophosphamid, rituximab) protokoll alkalmazásával.
  • B-cell prolymphocytic leukemia (B-PLL) is a rare disorder characterized by marked lymphocytosis in the peripheral blood, matured lymphocytic infiltration in the bone marrow and splenomegaly.
  • The authors present a case of a patient with typical B-PLL treated with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol achieving complete hematological (and immunophenotypic) remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Prolymphocytic, B-Cell / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Humans. Immunophenotyping. Male. Prognosis. Rituximab. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20656663.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


10. Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D: IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia; 2006 Jul;20(7):1231-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
  • B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis.
  • To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL.
  • [MeSH-major] Antigens, CD38 / genetics. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic / genetics. Membrane Glycoproteins / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642047.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; 0 / Membrane Glycoproteins; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


11. Inoue T, Yoshida M, Oowashi K, Yoshida T: [CD5-positive B-cell prolymphocytic leukemia]. Rinsho Ketsueki; 2010 Jan;51(1):80-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD5-positive B-cell prolymphocytic leukemia].
  • CD5 is a T-cell marker that is expressed in mature B cell malignancies and other B cell chronic lymphoproliferative disorders, but the biologic function of CD5 is unknown.
  • We report a 68-year-old woman with B-cell prolymphocytic leukemia (B-PLL) expressing CD5 antigen.
  • Hematological examination demonstrated a platelet count of 2.8 x 10(4)/microl and a white blood cell count of 19,900/microl with 69% PLL cells.
  • [MeSH-major] Antigens, CD5 / blood. Biomarkers, Tumor / blood. Leukemia, Prolymphocytic, B-Cell / blood. Leukemia, Prolymphocytic, B-Cell / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Female. Humans. Leukocyte Count. Platelet Count

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134145.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD5; 0 / Biomarkers, Tumor
  •  go-up   go-down


12. Dungarwalla M, Matutes E, Dearden CE: Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol; 2008 Jun;80(6):469-76
MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper.
  • Prolymphocytic leukaemias of B and T cell subtype are rare diseases.
  • Despite recent advances in immunophenotyping and molecular cytogenetics, leading to a better understanding of the underlying cell biology of the prolymphocytic leukaemias, prognosis for these patients remains poor.
  • Purine analogues and monoclonal antibodies have shown efficacy in B-cell prolymphocytic leukaemia although further studies are warranted.
  • Monoclonal antibody therapy with alemtuzumab has significantly improved outcome in T-cell prolymphocytic leukaemia (T-PLL) but responses are still transient and further disease progression is inevitable.
  • While allogeneic stem cell transplant is an attractive option, due to the older age group of T-PLL patients the morbidity and mortality associated with the procedure is significant.
  • [MeSH-major] B-Lymphocytes / immunology. Leukemia, Lymphoid / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Disease Progression. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331594.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  • [Number-of-references] 49
  •  go-up   go-down


13. Ogasawara T, Narita C, Kawauchi K: Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia. Leuk Res; 2007 Mar;31(3):403-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of vascular endothelial growth factor in T-cell prolymphocytic leukemia.
  • We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid.
  • Immunophenotyping of leukemia cells revealed either CD3+CD4+CD8-CD25+ or CD3+CD4+CD8+CD25+.
  • The antibody against human T-cell lymphotropic virus type I was negative.
  • A diagnosis of T-PLL was made.
  • Moreover, polymerase chain reaction analysis demonstrated an expression of VEGF mRNA in the leukemia cells, indicating a production of VEGF from leukemia cells and its involvement in the pathogenesis of T-PLL.
  • [MeSH-major] Leukemia, Prolymphocytic / immunology. Leukemia, T-Cell / immunology. Vascular Endothelial Growth Factor A / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620970.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


14. Toyota S, Nakamura N, Dan K: Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype. Int J Hematol; 2005 Jan;81(1):66-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant of T-cell prolymphocytic leukemia with a gammadelta immunophenotype.
  • T-cell prolymphocytic leukemia (T-PLL) is a rare postthymic T-cell disorder.
  • The disease is characterized by lymphadenopathy, splenomegaly, skin lesions, a high white blood cell count, and an aggressive clinical course.
  • The small cell variant of T-PLL occurs in approximately 20% of patients.
  • Most T-PLL patients express membrane T-cell receptors (TCR) of the alphabeta phenotype.
  • The diagnosis of small cell variant T-PLL in a 56-year-old woman was based on the findings of abnormal lymphocytosis, immunophenotype, lymphadenopathy, and aggressive clinical behavior.
  • This case was typical T-PLL except for the morphologically small cell type and the lack of the typical chromosome aberration.
  • If cases accumulate in the future, the specific features of the gamma8 type of T-PLL will become clearer.
  • [MeSH-major] Leukemia, Prolymphocytic / pathology. Leukemia, T-Cell / pathology. Receptors, Antigen, T-Cell, gamma-delta / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2142-52 [11304766.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Ann Hematol. 2001 Dec;80(12):749-51 [11797117.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1792-8 [12419753.001]
  • [Cites] J Exp Med. 1989 Apr 1;169(4):1277-94 [2564416.001]
  • [Cites] Br J Haematol. 1986 Sep;64(1):111-24 [3489482.001]
  • [Cites] Am J Pathol. 1988 Sep;132(3):401-5 [3261945.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):617-28 [1698028.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):753-5 [9674751.001]
  • [Cites] Blood. 2004 Jul 15;104(2):328-35 [15044256.001]
  • [Cites] Int J Hematol. 1999 Apr;69(3):186-95 [10222658.001]
  • [Cites] Blood. 1987 Oct;70(4):926-31 [3115337.001]
  • [Cites] Nature. 1984 Apr 26-May 2;308(5962):858-60 [6609313.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1453-5 [8751461.001]
  • (PMID = 15717692.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


15. Absi A, Hsi E, Kalaycio M: Prolymphocytic leukemia. Curr Treat Options Oncol; 2005 May;6(3):197-208
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolymphocytic leukemia.
  • Prolymphocytic leukemia is a rare chronic lymphoproliferative disorder that includes two subtypes, B cell and T cell, each with its own distinct clinical, laboratory and pathological features.
  • T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy.
  • We recommend alemtuzumab as initial therapy and offer stem cell transplant (SCT) to selected young, healthy patients who respond.
  • Although B-cell prolymphocytic leukemia is also a progressive disease, some patients can achieve a prolonged progression-free-survival with fludarabine.
  • Rituximab is a promising agent and further investigations are warranted to better define its role in treatment of this disorder.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, B-Cell / therapy. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / administration & dosage. Female. Humans. Male. Pentostatin / administration & dosage. Rituximab. Stem Cell Transplantation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):376-88 [11208829.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):169-79 [10194135.001]
  • [Cites] Am J Hematol. 2003 Oct;74(2):145-7 [14508807.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):230-1 [10706770.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):137-9 [11168523.001]
  • [Cites] Leukemia. 1994 Oct;8(10):1640-5 [7523797.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Acta Haematol. 1999;102(2):94-8 [10529513.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):571-81 [11293906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3885-9 [9520462.001]
  • [Cites] Eur J Haematol. 1996 Apr;56(4):235-40 [8641392.001]
  • [Cites] Clin Lymphoma. 2004 Mar;4(4):220-7 [15072613.001]
  • [Cites] Br J Haematol. 1997 Mar;96(4):724-32 [9074412.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):488-94 [9827924.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):1-9 [1913594.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):570-4 [7884417.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):37-43 [8996122.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2667-72 [9215839.001]
  • [Cites] Nat Med. 1997 Oct;3(10):1155-9 [9334731.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] Ann Hematol. 2004 May;83(5):319-21 [15060751.001]
  • [Cites] Am J Hematol. 1992 May;40(1):71-2 [1566752.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):391-4 [14663643.001]
  • [Cites] Semin Oncol. 1990 Oct;17(5 Suppl 8):66-70 [1699285.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3555-61 [14506141.001]
  • [Cites] Eur J Haematol. 1997 Jan;58(1):46-50 [9020373.001]
  • [Cites] Bone Marrow Transplant. 1996 Mar;17(3):371-5 [8704689.001]
  • [Cites] Eur J Haematol. 1992 Jul;49(1):46-7 [1499697.001]
  • [Cites] Hematol Pathol. 1987;1(1):27-33 [3509770.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1305-11 [9264385.001]
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1821 [1357112.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3269-74 [1742486.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12 Suppl 2:S15-9 [11508932.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):981-7 [11697653.001]
  • [Cites] J Biol Chem. 1995 Mar 17;270(11):6088-99 [7890742.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] Br J Haematol. 1997 Mar;96(3):617-9 [9054672.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1284-5 [7738636.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):580 [8790162.001]
  • [Cites] Leuk Res. 1998 Feb;22(2):185-91 [9593475.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):205-13 [11773171.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):157-9 [8611452.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):149-51 [11908720.001]
  • [Cites] Jpn J Clin Oncol. 1998 Apr;28(4):267-9 [9657013.001]
  • [Cites] Ann Hematol. 1998 Feb;76(2):85-6 [9540763.001]
  • [Cites] Cancer Treat Res. 1993;64:105-19 [7680874.001]
  • [Cites] Clin Lymphoma. 2002 Sep;3(2):105-10 [12435283.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):114-20 [12491512.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • (PMID = 15869731.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 395575MZO7 / Pentostatin; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 54
  •  go-up   go-down


16. Jahanmehr SA, Rogers M, Zheng J, Lai R, Wang C: Quantitation of cytological parameters of malignant lymphocytes using computerized image analysis. Int J Lab Hematol; 2008 Aug;30(4):278-85

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, image analysis program was used to quantitate cytological parameters of lymphocytes in B-cell lymphoproliferative disorders.
  • Chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and B-cell prolymphocytic leukemia (B-PLL) were selected to represent typically small, medium, and large-sized lymphocytes, respectively.
  • A set of measurements was generated for quantitation of total cell area, cell diameter, cytoplasm area, nuclear area, nuclear/cell ratio, and nuclear density.
  • The results from image analysis may assist in defining morphological criteria and in developing quantitative cell morphology.
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Prolymphocytic, B-Cell / pathology. Lymphoma, Mantle-Cell / pathology. Microscopy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665824.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Tarsitano M, Palmieri S, Ferrara F, Riccardi C, Cavaliere ML, Vicari L: Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia. Cancer Genet Cytogenet; 2009 Dec;195(2):164-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of the t(11;14)(q13;q32) without CCND1/IGH fusion in a case of acute myeloid leukemia.
  • The t(11;14)(q13;q32) is a hallmark of mantle cell lymphoma.
  • It has been found less frequently in other lymphoproliferative disorders, such as B-prolymphocytic leukemia, plasma cell leukemia, chronic lymphocytic leukemia, and multiple myeloma.
  • Here, we describe a patient with acute myeloid leukemia (AML), categorized as M5b according to French-American-British classification, in which conventional cytogenetic analysis revealed a karyotype with t(11;14)(q13;q32).
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Myeloid, Acute / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963117.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


18. Zhang YN, Zhou XG, Zhang SH, Wang P, Zhang CH, Huang SF: [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2005 Apr;34(4):193-7
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 369 B-cell non-Hodgkin lymphoma cases, with reference to the 2001 World Health Organization classification of lymphoid neoplasms].
  • OBJECTIVE: To describe the relative frequency, morphologic features, immunophenotype and clinical data of different types of B-cell non-Hodgkin lymphoma (B-NHL) and to evaluate the practical application of the 2001 World Health Organization (WHO) classification of lymphoid neoplasms.
  • Diffuse large B-cell lymphoma, extranodal marginal zone lymphoma and follicular lymphoma were the commonest subtypes, accounting for 51.2% (189 cases), 14.9% (55 cases) and 10.6% (39 cases) of all cases respectively.
  • B-cell prolymphocytic leukemia and hairy cell leukemia were not identified.
  • When comparing the diagnosis based on morphologic examination alone with the diagnosis based on both morphology and immunophenotype, there was a 80% concordance rate.
  • Immunohistochemical study was helpful in reaching the correct diagnosis in many cases and could improve the overall diagnostic accuracy by about 20%.
  • CONCLUSIONS: Amongst cases of B-NHL, diffuse large B-cell lymphoma is the commonest subtype, followed by MALToma and follicular lymphoma.
  • While morphologic examination forms the basis for lymphoma diagnosis, immunohistochemical study also plays an important role in further subtyping.
  • A combination of both modalities are sufficient for arriving at an accurate diagnosis in most cases of B-NHL, in keeping with the recommendation of the 2001 WHO classification of lymphoid neoplasms.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / classification

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091170.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD43; 0 / Antigens, CD79
  •  go-up   go-down


19. Okamura K, Ikeda T, Shimakura Y, Yoshiba F, Kishi K, Ando K, Hotta T: [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia]. Rinsho Ketsueki; 2005 Jul;46(7):527-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic bone marrow transplantation for chemotherapy-resistant T-prolymphocytic leukemia].
  • Leukocyte count at diagnosis was 17,900/microl with 58% atypical lymphocytes having a convoluted nucleus and prominent nucleoli.
  • The patient was treated with Ara-C and etoposide before conditioning to decrease the high leukemia burden.
  • Because 9.4% of residual recipient type T-cells was seen with STR analysis on day 22, we decreased the dose of Cs'A.
  • After the occurrence of mild acute GVHD, the residual T-cell number decreased.
  • [MeSH-major] Bone Marrow Transplantation. Graft vs Leukemia Effect. Leukemia, Prolymphocytic / therapy. Leukemia, T-Cell / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Graft vs Host Disease / prevention & control. Humans. Remission Induction. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440747.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


20. Watanabe N, Takahashi T, Sugimoto N, Tanaka Y, Kurata M, Matsushita A, Maeda A, Nagai K, Nasu K: Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab. Int J Clin Oncol; 2005 Oct;10(5):357-61
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab.
  • A 70-year-old woman was diagnosed with B-cell-type chronic lymphocytic leukemia (B-CLL) in May 2001.
  • Initial white blood cell (WBC) count was 37 x 10(9)/l and most of the cells were mature small lymphocytes.
  • The surface phenotype of these cells was identical to that of circulating lymphocytes, indicating meningeal involvement of leukemia, a rare complication in B-CLL.
  • At the time of this WBC elevation, 24% of circulating lymphocytes had prominent nucleoli, indicating progression of the disease to CLL/prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Meningeal Neoplasms / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3266-74 [9336364.001]
  • [Cites] Scand J Haematol. 1982 Oct;29(4):283-6 [7178833.001]
  • [Cites] Cancer. 1979 May;43(5):1858-61 [445372.001]
  • [Cites] Acta Haematol. 1992;88(1):37-40 [1414160.001]
  • [Cites] Cancer. 1985 May 1;55(9):1937-42 [3872161.001]
  • [Cites] N Engl J Med. 1993 Jan 28;328(4):266-75 [8418408.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2217-24 [10498591.001]
  • [Cites] Acta Haematol. 1992;87(3):163-4 [1642098.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1714-6 [2790684.001]
  • [Cites] Cancer. 1982 Aug 1;50(3):605-6 [6980044.001]
  • [Cites] Arch Pathol Lab Med. 1997 May;121(5):524-7 [9167611.001]
  • [Cites] J Comput Assist Tomogr. 1982 Aug;6(4):812-4 [7119204.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):791-4 [9034157.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Acta Haematol. 1986;75(2):113-5 [3090818.001]
  • [Cites] Can J Neurol Sci. 1992 May;19(2):239-42 [1623453.001]
  • [Cites] Am J Hematol. 1992 Aug;40(4):259-63 [1380203.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2188-95 [9310469.001]
  • [Cites] Blood. 1995 Aug 1;86(3):1163-9 [7620169.001]
  • [Cites] J Neurooncol. 1993 Apr;16(1):35-7 [8410140.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):191-2 [3594356.001]
  • [Cites] Blood. 1981 Mar;57(3):526-30 [6970053.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Clin Pathol. 1989 Jun;42(6):567-84 [2738163.001]
  • [Cites] Cancer. 1978 Dec;42(6):2920-7 [310337.001]
  • [Cites] Blood. 1979 Jun;53(6):1066-75 [375999.001]
  • [Cites] J Formos Med Assoc. 2000 Oct;99(10):775-8 [11061073.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Cancer. 1981 May 15;47(10):2482-4 [6895047.001]
  • [Cites] Cancer. 1987 Feb 15;59(4):798-800 [3802037.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1235-7 [12916878.001]
  • (PMID = 16247665.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


21. Fidani L, Hatzitolios AI, Goulas A, Savopoulos C, Basayannis C, Kotsis A: Cholesteryl ester transfer protein TaqI B and lipoprotein lipase Ser447Ter gene polymorphisms are not associated with ischaemic stroke in Greek patients. Neurosci Lett; 2005 Aug 12-19;384(1-2):102-5
Hazardous Substances Data Bank. L-SERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cholesteryl ester transfer protein (CETP) and lipoprotein lipase (LPL) are both key players in plasma lipoprotein homeostasis and, as such, genetically induced alterations in their respective activities may affect susceptibility to cerebrovascular diseases.
  • In this study, we examined the distribution of two common polymorphisms, namely CETP TaqI B and LPL Ser447Ter in a cohort of Greek clinically diagnosed late-onset ischaemic stroke patients (n = 98) and an ethnicity-, age- and sex-matched control group with no manifestations of vascular disease (n = 100).
  • [MeSH-minor] Aged. Aged, 80 and over. Case-Control Studies. Cholesterol Ester Transfer Proteins. Female. Gene Frequency. Genetic Predisposition to Disease. Greece / epidemiology. Humans. Male. Odds Ratio

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896905.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CETP protein, human; 0 / Carrier Proteins; 0 / Cholesterol Ester Transfer Proteins; 0 / Glycoproteins; 452VLY9402 / Serine; EC 3.1.1.34 / Lipoprotein Lipase
  •  go-up   go-down


22. Klobusicka M, Kusenda J, Stevulova L, Kovarikova A, Babusikova O: Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia. Neoplasma; 2010;57(5):429-37
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible prognostic value of nucleolar morphology in pathologic cells of B-chronic lymphocytic leukemia.
  • B-cell chronic lymphocytic leukemia (B-CLL) represents a heterogeneous disease with a very variable outcome.
  • The reliable prognosis of this disease at the time of initial diagnosis is difficult to predict.
  • The purpose of this preliminary study was to utilize the nucleolar morphology and to investigate the incidence of main nucleolar types in leukemic lymphocytes in B-CLL patients to assess their possible predictive value for the disease outcome, in correlation with immunophenotype parameters.
  • The evaluation of nucleolar morphology of pathologic lymphocytes was performed at diagnosis and during the course of disease.
  • Median follow up period of patients was 16.4 months (range from 2 to 32 months) from diagnosis.
  • The presence of ring shaped and compact nucleoli in leukemic lymphocytes divided patients into two subgroups with different outcome of the disease.
  • The population of leukemic cells of a small group of B-CLL patients (Group 2, 13 patients, 15.4%) was characterized by the presence of various proportions of pathologic lymphocytes with one large compact nucleolus.Different response to the therapy discriminated the B-CLL patients whose leukemic lymphocytes revealed evident compact nucleoli at presentation, to next two subsets.
  • None of our B-CLL patients had the signs of transformation to prolymphocytic or other type of B cell neoplasms during the follow up.
  • The simplicity and utility of the nucleolar test as a possible prognostic parameter may help to identify the subset of patients with early B-CLL disease that will run a more progressive course.
  • [MeSH-major] Cell Nucleolus / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphocytes / ultrastructure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568897.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


23. Wang J, Hasui K, Utsunomiya A, Jia X, Matsuyama T, Murata F: Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL. J Clin Exp Hematop; 2008 Apr;48(1):1-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of high proliferation in adult T-cell leukemia cells with apoptosis, and expression of p53 protein in acute type ATL.
  • Proliferation, apoptosis and p53 protein expression in adult T-cell leukemia (ATL) cells were investigated.
  • Twenty peripheral blood tissue specimens (PBTS) comprising 7 cases of acute type ATL, 7 cases of chronic type ATL and 6 other leukemias were examined by means of antigen retrieval and the polymer method employing anti-Ki67 antigen (MIB-1), anti-cleaved caspase-3, anti-single stranded DNA and three kinds of anti-p53 protein antibodies including DO7.
  • Most acute and chronic cases of ATL included more than 10% MIB-1-positive proliferating leukemia cells and more than 1% cleaved caspase-3-positive apoptotic cells.
  • Some cells which were positive for both MIB-1 and anti-cleaved caspase-3 antibody were observed in acute type ATL.
  • Nuclear deposition of p53 protein labeled by DO7 was often found in acute type (p < 0.05).
  • Within the medium-sized population of ATL cell nuclei, DO7-positive ATL cells had a smaller nuclear area factor (long axis x short axis) than DO7-negative ATL cells.
  • A few proliferating ATL cells entered apoptosis, and the appearance of a subclone of ATL cells with nuclear deposition of p53 protein labeled by DO7 characterized acute type.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434687.001).
  • [ISSN] 1346-4280
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


24. Kurihara K, Harashima N, Hanabuchi S, Masuda M, Utsunomiya A, Tanosaki R, Tomonaga M, Ohashi T, Hasegawa A, Masuda T, Okamura J, Tanaka Y, Kannagi M: Potential immunogenicity of adult T cell leukemia cells in vivo. Int J Cancer; 2005 Mar 20;114(2):257-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential immunogenicity of adult T cell leukemia cells in vivo.
  • Experimental vaccines targeting human T cell leukemia virus type-I (HTLV-I) Tax have been demonstrated in a rat model of HTLV-I-induced lymphomas.
  • However, the scarcity of HTLV-I-expression and the presence of defective HTLV-I-proviruses in adult T cell leukemia (ATL) cells have raised controversy about the therapeutic potential of HTLV-I-targeted immunotherapy in humans.
  • In flow cytometric analysis, we found that 3 of 5 acute-type and six of fifteen chronic-type ATL patients tested showed significant induction of HTLV-I Tax and Gag in their ATL cells in a 1-day culture.
  • Representative CTL epitopes restricted by HLA-A2 or A24 were conserved in 4 of 5 acute-type ATL patients tested.
  • Furthermore, spleen T cells from rats, which had been subcutaneously inoculated with formalin-fixed uncultured ATL cells, exhibited a strong interferon gamma-producing helper T cell responses specific for HTLV-I Tax-expressing cells.
  • Our study indicated that ATL cells from about half the patients tested readily express HTLV-I antigens including Tax in vitro, and that ATL cells express sufficient amounts of Tax or Tax-induced antigens to evoke specific T cell responses in vivo.
  • [MeSH-minor] Adult. Aged. Animals. Base Sequence. DNA Primers. Female. Humans. Japan. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia, Prolymphocytic, T-Cell / virology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Male. Middle Aged. Polymerase Chain Reaction. Rats. Rats, Inbred F344. Reference Values. Transplantation, Heterologous / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15551352.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


25. Dixit M, Choudhuri G, Mittal B: Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study. Hepatol Res; 2006 Sep;36(1):61-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of lipoprotein receptor, receptor-associated protein, and metabolizing enzyme gene polymorphisms with gallstone disease: A case-control study.
  • INTRODUCTION: To identify high risk alleles for gallstone disease, we analyzed association of LDLRAvaII, LRPAP1 insertion/deletion, CETPTaqI B, and LPLHindIII polymorphisms with gallstone disease.
  • RESULTS: LRPAP1 gene insertion/deletion polymorphism was found to be significantly associated with gallstone disease.
  • Genotype II was conferring significant risk for gallstone disease in females only (P=0.019; OR 2.577, 95% CI 1.144-5.806).
  • LDLRAvaII, CETPTaqI B, and LPLHindIII polymorphisms were not found to be associated with gallstone disease either at genotype or allele level.
  • CONCLUSIONS: LRPAP1, II genotype carrier females may have increased risk for gallstone disease.
  • On the other hand, LDLR AvaII, CETP TaqI B, and LPL HindIII polymorphisms may not be associated with gallstone disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16837242.001).
  • [ISSN] 1386-6346
  • [Journal-full-title] Hepatology research : the official journal of the Japan Society of Hepatology
  • [ISO-abbreviation] Hepatol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


26. Chen J, Petrus M, Bryant BR, Nguyen VP, Goldman CK, Bamford R, Morris JC, Janik JE, Waldmann TA: Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia. Blood; 2010 Dec 23;116(26):5948-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.
  • Adult T-cell leukemia (ATL), a heterogeneous disease, can be divided into smoldering, chronic, lymphoma, and acute types clinically.
  • Here, we demonstrated that smoldering/chronic ATL peripheral blood mononuclear cells spontaneously proliferated ex vivo in a cytokine (interleukin-12 [IL-12]/IL-9/IL-15)-dependent manner, while acute-type ATL peripheral blood mononuclear cells did not proliferate or proliferated independent of cytokines.
  • In conclusion, our data provide evidence that there is autocrine/paracrine cytokine stimulation of leukemic cell proliferation in patients with smoldering/chronic ATL that could be targeted for treatment.

  • Genetic Alliance. consumer health - Leukemia, T-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1043-8 [10706122.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4624-33 [15735688.001]
  • [Cites] Immunity. 2002 Nov;17(5):537-47 [12433361.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6390-4 [12438221.001]
  • [Cites] J Immunol Methods. 2003 Jul;278(1-2):221-34 [12957410.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Blood. 1981 Sep;58(3):645-7 [6455129.001]
  • [Cites] Science. 1984 Mar 9;223(4640):1086-7 [6320374.001]
  • [Cites] J Immunol. 1987 May 1;138(9):3069-74 [2883237.001]
  • [Cites] Blood. 1987 Nov;70(5):1407-11 [2889484.001]
  • [Cites] Neurology. 1988 Aug;38(8):1302-7 [2899862.001]
  • [Cites] Leukemia. 1988 Nov;2(11):728-33 [2972890.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(13):5218-22 [2367534.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Immunol. 1992 May 15;148(10):3256-63 [1374452.001]
  • [Cites] Am J Hematol. 1992 Dec;41(4):258-63 [1288288.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):741-50 [8094736.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1701-12 [8400227.001]
  • [Cites] Leukemia. 1994 Apr;8(4):652-8 [8152260.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 May;1(3):273-82 [7496962.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):479-87 [9389355.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2452-7 [9482906.001]
  • [Cites] Microbiol Mol Biol Rev. 1999 Jun;63(2):308-33 [10357853.001]
  • [Cites] Trends Mol Med. 2004 Nov;10(11):532-41 [15519279.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1648-53 [16646068.001]
  • [Cites] Oncogene. 2007 Feb 22;26(8):1245-55 [16909099.001]
  • [Cites] Nat Med. 2007 May;13(5):527-8 [17479090.001]
  • [Cites] Int J Oncol. 2007 Jun;30(6):1343-8 [17487354.001]
  • [Cites] Int Arch Allergy Immunol. 2007;143 Suppl 1:71-5 [17541281.001]
  • [Cites] Blood. 2008 May 15;111(10):5163-72 [18339896.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2400-10 [18509087.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Am J Pathol. 2010 Jan;176(1):402-15 [20019193.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2602-9 [11160322.001]
  • (PMID = 20858854.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cytokines
  • [Other-IDs] NLM/ PMC3031384
  •  go-up   go-down


27. Meyers JA, Su DW, Lerner A: Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors. J Immunol; 2009 May 1;182(9):5400-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia and B and T cells differ in their response to cyclic nucleotide phosphodiesterase inhibitors.
  • Phosphodiesterase (PDE)4 inhibitors, which activate cAMP signaling by reducing cAMP catabolism, are known to induce apoptosis in B lineage chronic lymphocytic leukemia (CLL) cells but not normal human T cells.
  • Affymetrix gene chip analysis in the three cell populations following treatment with the PDE4 inhibitor rolipram identified a set of up-regulated transcripts with unusually high fold changes in the CLL samples, several of which are likely part of compensatory negative feedback loops.
  • The high fold changes were due to low basal transcript levels in CLL cells, suggesting that cAMP-mediated signaling may be unusually tightly regulated in this cell type.
  • Rolipram treatment augmented cAMP levels and induced ATF-1/CREB serine 63/133 phosphorylation in both B lineage cell types but not T cells.
  • As treatment with the broad-spectrum PDE inhibitor 3-isobutyl-1-methylxanthine induced T cell CREB phosphorylation, we tested a series of family-specific PDE inhibitors for their ability to mimic 3-isobutyl-1-methylxanthine-induced ATF-1/CREB phosphorylation.
  • Combined PDE3/4 inhibition did not induce T cell apoptosis, suggesting that cAMP-mediated signal transduction that leads to robust ATF-1/CREB serine 63/133 phosphorylation is not sufficient to induce apoptosis in this lymphoid lineage.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Reprod Dev. 2000 Jun;56(2 Suppl):228-9 [10824972.001]
  • [Cites] Biochem Pharmacol. 2005 Feb 1;69(3):473-83 [15652238.001]
  • [Cites] Br J Pharmacol. 2000 Dec;131(8):1607-18 [11139438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 22;98(11):6319-24 [11371644.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):509-19 [11395427.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Oct;281(4):L832-43 [11557587.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):589-95 [11839681.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7728-33 [12032351.001]
  • [Cites] Biochem J. 2003 Feb 15;370(Pt 1):1-18 [12444918.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1101-8 [12718894.001]
  • [Cites] Blood. 2003 May 15;101(10):4122-30 [12531792.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2661-7 [14615375.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20858-65 [14996839.001]
  • [Cites] Mol Cell Endocrinol. 2004 Aug 31;223(1-2):55-62 [15279911.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):42438-44 [15299028.001]
  • [Cites] J Immunol. 2004 Oct 15;173(8):4847-58 [15470025.001]
  • [Cites] Endocrinology. 2004 Nov;145(11):5177-84 [15284208.001]
  • [Cites] Biochem J. 1987 Apr 15;243(2):533-9 [2820385.001]
  • [Cites] Biochem Pharmacol. 1991 Jul 25;42(4):869-77 [1651080.001]
  • [Cites] Nucleic Acids Res. 1993 Jun 11;21(11):2715-21 [7687344.001]
  • [Cites] Cell. 1993 Dec 3;75(5):875-86 [8252624.001]
  • [Cites] J Immunol. 1995 Feb 15;154(4):1634-43 [7836748.001]
  • [Cites] Cell Signal. 1996 Feb;8(2):97-110 [8730511.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11236-41 [8855339.001]
  • [Cites] Br J Pharmacol. 1996 Aug;118(8):1945-58 [8864528.001]
  • [Cites] Br J Pharmacol. 1997 May;121(2):221-31 [9154331.001]
  • [Cites] Oncogene. 1997 Aug 14;15(7):827-36 [9266969.001]
  • [Cites] Br J Haematol. 1997 Dec;99(4):784-9 [9432022.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2484-94 [9746789.001]
  • [Cites] Science. 1999 Feb 5;283(5403):848-51 [9933169.001]
  • [Cites] Biochem Pharmacol. 1999 Sep 15;58(6):935-50 [10509746.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D562-6 [15608262.001]
  • [Cites] Biostatistics. 2005 Jan;6(1):59-75 [15618528.001]
  • [Cites] Cell. 2004 Dec 29;119(7):1041-54 [15620361.001]
  • [Cites] Genome Biol. 2005;6(2):R16 [15693945.001]
  • [Cites] Curr Opin Pharmacol. 2005 Jun;5(3):238-44 [15907909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8561-6 [15939874.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2357-65 [16081806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14771-6 [16186489.001]
  • [Cites] Biochem J. 2006 Jan 1;393(Pt 1):21-41 [16336197.001]
  • [Cites] Nat Genet. 2006 May;38(5):500-1 [16642009.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6333-46 [16914720.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):112-21 [17200714.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4920-7 [17699872.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Sep;16(9):1489-506 [17714033.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Oct;16(10):1585-99 [17922623.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Curr Biol. 2000 Oct 19;10(20):1291-4 [11069111.001]
  • (PMID = 19380787.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA106705-04; United States / NCI NIH HHS / CA / R01 CA106705; United States / NCI NIH HHS / CA / CA106705; United States / NCI NIH HHS / CA / CA106705-04; United States / NHLBI NIH HHS / HL / T32 HL007501-27; United States / NHLBI NIH HHS / HL / HL007501-27; United States / NHLBI NIH HHS / HL / T32 HL007501; United States / NHLBI NIH HHS / HL / HL007501
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphodiesterase 3 Inhibitors; 0 / Phosphodiesterase 4 Inhibitors; E0399OZS9N / Cyclic AMP
  • [Other-IDs] NLM/ NIHMS108934; NLM/ PMC2676892
  •  go-up   go-down


28. Bacher U, Haferlach T, Schnittger S, Weiss T, Burkhard O, Bechtel B, Kern W, Haferlach C: Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia. Cancer Genet Cytogenet; 2010 Jul 15;200(2):170-4
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.
  • Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibroblast growth factor receptor 3).
  • In a minority of patients with B-lineage chronic lymphocytic leukemia (CLL), reciprocal IGH/14q32 translocations have been reported as well.
  • We describe the occurrence of a t(4;14)(p16;q32) in two lymphoma patients showing the immunophenotype of B-CLL, which, to our knowledge, is the first report on such an association.
  • Immunophenotyping revealed the phenotype of CLL/PLL (chronic lymphocytic leukemia/prolymphocytic leukemia).
  • These two cases with an t(4;14), but the immunophenotype of B-CLL, demonstrate the genetic variability of B-cell lymphomas and the potential of specific metaphase cultivation techniques using oligonucleotides to increase our insights in the genetic pathways of these heterogeneous disorders.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 4. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell / genetics. Translocation, Genetic
  • [MeSH-minor] Aged. Female. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Male. Receptor, Fibroblast Growth Factor, Type 3 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20620602.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; EC 2.7.10.1 / FGFR3 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


29. Feldman AL, Law M, Grogg KL, Thorland EC, Fink S, Kurtin PJ, Macon WR, Remstein ED, Dogan A: Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization. Am J Clin Pathol; 2008 Aug;130(2):178-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of TCR and TCL1 gene translocations and isochromosome 7q in peripheral T-cell lymphomas using fluorescence in situ hybridization.
  • Translocations involving the T-cell receptor (TCR) and TCL1 genes occur in T-cell precursor lymphoblastic leukemia/lymphoma and prolymphocytic leukemia; isochromosome 7q has been associated with hepatosplenic T-cell lymphoma.
  • However, the incidence of these abnormalities in peripheral T-cell lymphomas (PTCLs) as a whole has not been well defined.
  • Isochromosome 7q was detected in 2 cases of extranodal NK/T-cell lymphoma, nasal type, and 2 cases of anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 2000 Feb;117(1):71-9 [10700871.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1546-53 [17122510.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):285-96 [11224598.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] JAMA. 2001 Nov 14;286(18):2308-14 [11710897.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):1967-72 [12057901.001]
  • [Cites] Leukemia. 2003 Apr;17(4):738-45 [12682631.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1467-75 [15367405.001]
  • [Cites] Science. 1984 Jun 29;224(4656):1403-6 [6610211.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):382-90 [3546615.001]
  • [Cites] Am J Hematol. 1990 Oct;35(2):88-95 [2399910.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Aug;55(1):1-9 [1913594.001]
  • [Cites] Genes Chromosomes Cancer. 1993 Dec;8(4):219-23 [7512364.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):221-30 [7522535.001]
  • [Cites] Leukemia. 1997 Aug;11(8):1367-72 [9264394.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2949-51 [10077617.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):241-50 [10439361.001]
  • [Cites] Adv Anat Pathol. 2005 Jan;12(1):27-34 [15614162.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6 Suppl 16):18-21; discussion 33 [15799240.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):421-9 [16191511.001]
  • [Cites] Genet Med. 2006 Jan;8(1):16-23 [16418595.001]
  • [Cites] Leukemia. 2006 Feb;20(2):313-8 [16341044.001]
  • [Cites] Blood. 2006 Jul 1;108(1):401-2; author reply 402-3 [16790585.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • (PMID = 18628085.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / Receptors, Antigen, T-Cell; 0 / TCL1A protein, human
  • [Other-IDs] NLM/ NIHMS454017; NLM/ PMC3625137
  •  go-up   go-down


30. Matutes E, Wotherspoon A, Catovsky D: Differential diagnosis in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol; 2007 Sep;20(3):367-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis in chronic lymphocytic leukaemia.
  • The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features.
  • In cases with atypical features, these investigations should be complemented with cytogenetics and/or histology to confirm the diagnosis and to exclude other B-cell disorders.
  • Cell-marker studies provide a robust foundation to establish the diagnosis as the lymphocytes have a distinct immunophenotypic signature.
  • Although no single antigen is exclusively expressed in CLL cells, when several markers are compounded into a scoring system the results allow firming up of the diagnosis.
  • Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Bone Marrow / pathology. Diagnosis, Differential. Flow Cytometry. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Leukemia, Hairy Cell / diagnosis. Leukemia, Prolymphocytic / diagnosis. Lymphocytes / pathology. Prognosis. Spleen / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17707827.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Troussard X, Cornet E: Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes. Curr Treat Options Oncol; 2007 Apr;8(2):97-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SLVL is a rare leukemic and indolent B-cell chronic lymphoproliferative disorder (B-CLPD) that we have to differentiate from hairy cell leukemia (HCL), B prolymphocytic leukemia (B-PLL) and follicular lymphoma (FL).
  • However, the diagnosis can be difficult to make on morphological criteria, especially in patients without absolute lymphocytosis.
  • SLVL has a relatively clinical benign course but a few patients could require treatment, because of a symptomatic splenomegaly and/or a severe cytopenia.
  • [MeSH-major] B-Lymphocytes / pathology. Lymphoma, B-Cell / therapy. Splenic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Lymphoma. 2002 Jun;3(1):41-7 [12141954.001]
  • [Cites] Blood. 2000 Mar 15;95(6):1950-6 [10706860.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1558-62 [8123845.001]
  • [Cites] Lancet. 1992 Sep 5;340(8819):575-7 [1355156.001]
  • [Cites] Br J Haematol. 2003 Mar;120(5):759-64 [12614206.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):712-21 [9674745.001]
  • [Cites] Br J Haematol. 1998 Mar;100(3):609 [9504654.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3552-8 [11369650.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2050-7 [15389479.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):158-61 [9359516.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):513-7 [16049984.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):404-12 [12877667.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):392-8 [16480431.001]
  • [Cites] Blood. 1995 Mar 15;85(6):1603-7 [7888678.001]
  • [Cites] Eur J Haematol. 2002 Aug;69(2):112-4 [12366716.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2727-37 [14630827.001]
  • [Cites] J Clin Pathol. 1992 Dec;45(12):1111-3 [1479039.001]
  • [Cites] J Clin Pathol. 1987 Jun;40(6):642-51 [3497180.001]
  • [Cites] Leuk Res. 1996 Nov-Dec;20(11-12):909-13 [9009248.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1212-3 [9886348.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):600-4 [10086800.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):731-6 [8652403.001]
  • [Cites] Haematologica. 2005 Apr;90(4):470-8 [15820942.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jan;36(1):57-69 [12461750.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1736-40 [9563492.001]
  • [Cites] Br J Haematol. 1993 Nov;85(3):487-91 [8136270.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Jul 1;96(1):13-6 [9209463.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2659-61 [12239182.001]
  • [Cites] Leuk Lymphoma. 2000 Dec;40(1-2):113-7 [11426611.001]
  • [Cites] Int J Hematol. 2005 Jun;81(5):413-6 [16158822.001]
  • [Cites] Trans R Soc Trop Med Hyg. 1997 Mar-Apr;91(2):171-4 [9196759.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1648-54 [12176884.001]
  • [Cites] Blood Rev. 2005 Jan;19(1):39-51 [15572216.001]
  • [Cites] Br J Haematol. 1991 Jun;78(2):206-9 [2064958.001]
  • [Cites] Eur J Haematol. 2006 Feb;76(2):134-40 [16405434.001]
  • [Cites] Leukemia. 2000 Apr;14(4):573-5 [10764141.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1924-5 [15385943.001]
  • [Cites] Eur J Haematol. 2005 Aug;75(2):130-5 [16000129.001]
  • (PMID = 17634839.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


32. Peggs KS, Mackinnon S, Linch DC: The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol; 2005 Jan;128(2):153-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although 40-60% of younger patients with diffuse large cell lymphoma can now expect to be cured, significant numbers will either fail to achieve a remission or relapse after attaining a remission.
  • In addition, certain histological subtypes are associated with particularly poor prognoses with combination chemotherapy alone (e.g. mantle cell lymphoma, B-cell prolymphocytic leukaemia).
  • Other NHL subtypes, whilst associated with more favourable prognoses in terms of overall survival, are rarely, if ever, cured (e.g. most low grade NHL including follicular lymphoma, chronic lymphocytic leukaemia and small lymphocytic lymphoma).
  • For these reasons dose escalation and allogeneic transplantation have been investigated as potential ways of improving outcome, although this has mainly been in the setting of advanced disease.
  • The parallel development of transplantation approaches that limit procedural toxicity along with advances in supportive care require that the role of allogeneic haematopoietic stem cell transplantation in the management of lymphoma be re-evaluated.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638849.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  •  go-up   go-down


33. Vasilj A, Kojić-Katović S, Maricević I, Zokvić E, Kelcec IB, Tomas D, Curić-Jurić S: Hodgkin's lymphoma variant of Richter's syndrome. Coll Antropol; 2010 Mar;34(1):295-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic lymphocytic leukemia/small lymphocitic lymphoma (CLL/SLL) is low-grade malignant lymphoprolipheration, that has tendency to convert to a higher-grade neoplasm over time.
  • More common is the development of a diffuse large cell lymphoma or transformation into prolymphocytic cell population.
  • In rare cases, 0.1-0.5% of patients develop multiple myeloma or Hodgkin's disease.
  • On the basis of clinical simptoms, cytological, hystological and immunohistological finding in April 2008 CLL/SLL were diagnosed.
  • The diagnosis was Hodgkin's disease.
  • Immuno-hystological studies of the lymph node was consistent with type I Hodgkin's type of Richter's syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437646.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


34. de la Fuente C, Gupta MV, Klase Z, Strouss K, Cahan P, McCaffery T, Galante A, Soteropoulos P, Pumfery A, Fujii M, Kashanchi F: Involvement of HTLV-I Tax and CREB in aneuploidy: a bioinformatics approach. Retrovirology; 2006 Jul 05;3:43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adult T-cell leukemia (ATL) is a complex and multifaceted disease associated with human T-cell leukemia virus type 1 (HTLV-I) infection.
  • Tax, the viral oncoprotein, is considered a major contributor to cell cycle deregulation in HTLV-I transformed cells by either directly disrupting cellular factors (protein-protein interactions) or altering their transcription profile.
  • Therefore by examining which factors upregulate a particular set of promoters we may begin to understand how Tax orchestrates leukemia development.
  • RESULTS: We observed that CTLL cells stably expressing wild-type Tax (CTLL/WT) exhibited aneuploidy as compared to a Tax clone deficient for CREB transactivation (CTLL/703).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2003 Jun 23;161(6):1067-79 [12810701.001]
  • [Cites] J Biol Chem. 1988 Jul 15;263(20):9879-86 [2454922.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3467-75 [2850495.001]
  • [Cites] Int J Cancer. 1989 Feb 15;43(2):250-3 [2917802.001]
  • [Cites] Science. 1990 Jan 26;247(4941):464-7 [2405488.001]
  • [Cites] Genome. 1989;31(2):662-7 [2698836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(22):8711-5 [2247439.001]
  • [Cites] Anal Biochem. 1990 Nov 1;190(2):266-70 [1705398.001]
  • [Cites] Oncogene. 1991 Jun;6(6):1023-9 [1906155.001]
  • [Cites] Oncogene. 1991 Oct;6(10):1851-7 [1833716.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Mol Cell Biol. 1992 Jun;12(6):2826-36 [1534143.001]
  • [Cites] Nature. 1992 Aug 6;358(6386):512-4 [1641041.001]
  • [Cites] Virology. 1993 Mar;193(1):456-9 [8438579.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):9-16 [8175926.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(15):5269-81 [12861013.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5141-9 [12910251.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37736-44 [12842897.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):21-6 [14557244.001]
  • [Cites] J Cell Biol. 2003 Oct 27;163(2):215-22 [14581449.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13314-9 [14585930.001]
  • [Cites] Cell. 2003 Oct 31;115(3):355-67 [14636562.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):339-42 [8090203.001]
  • [Cites] Nature. 1994 Sep 22;371(6495):342-5 [8090204.001]
  • [Cites] Semin Cancer Biol. 1994 Aug;5(4):285-94 [7803765.001]
  • [Cites] J Cell Biol. 1996 Feb;132(4):617-33 [8647893.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S179-85 [8797721.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1995;60:803-11 [8824455.001]
  • [Cites] Cell. 1996 Nov 1;87(3):447-58 [8898198.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6101-4 [9045619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9141-6 [9256449.001]
  • [Cites] Eur J Cell Biol. 1997 Sep;74(1):10-9 [9309386.001]
  • [Cites] Adv Second Messenger Phosphoprotein Res. 1997;31:191-204 [9344252.001]
  • [Cites] Cell. 1998 Apr 3;93(1):81-91 [9546394.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3620-32 [9584203.001]
  • [Cites] EMBO J. 1998 Aug 3;17(15):4370-8 [9687505.001]
  • [Cites] J Cell Biol. 1998 Aug 10;142(3):763-74 [9700164.001]
  • [Cites] Trends Cell Biol. 1998 Aug;8(8):310-8 [9704407.001]
  • [Cites] Cell Growth Differ. 1998 Aug;9(8):651-65 [9716182.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;41(2):154-67 [9786090.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):12906-11 [9789013.001]
  • [Cites] Science. 2000 May 5;288(5467):867-70 [10797011.001]
  • [Cites] J Virol. 2000 Aug;74(16):7270-83 [10906181.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6996-7006 [10958694.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • [Cites] Virology. 2001 Jan 5;279(1):38-46 [11145887.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):267-73 [11470816.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31851-7 [11435441.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7065-77 [11564889.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Mol Cell Biol. 2002 Jan;22(2):626-34 [11756557.001]
  • [Cites] Nat Cell Biol. 2001 Dec;3(12):1086-91 [11781570.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5187-93 [11729202.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Feb;128(2):114-8 [11862483.001]
  • [Cites] J Cell Biol. 2002 Jun 24;157(7):1125-37 [12070128.001]
  • [Cites] J Biomed Sci. 2002 Jul-Aug;9(4):292-8 [12145525.001]
  • [Cites] J Cell Sci. 2002 Sep 15;115(Pt 18):3547-55 [12186941.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7066-82 [12242286.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Virology. 2003 Jan 20;305(2):229-39 [12573569.001]
  • [Cites] Mol Biol Cell. 2003 Feb;14(2):685-97 [12589063.001]
  • [Cites] J Virol. 2003 Apr;77(8):4731-8 [12663780.001]
  • [Cites] Mol Cell Biochem. 2003 Mar;245(1-2):99-113 [12708749.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] J Gen Virol. 2003 Dec;84(Pt 12):3203-14 [14645902.001]
  • [Cites] Genes Dev. 2003 Dec 1;17(23):2902-21 [14633972.001]
  • [Cites] J Biol Chem. 2004 Jan 2;279(1):495-508 [14530271.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):1-39 [14715909.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):434-9 [14733924.001]
  • [Cites] Genes Immun. 2004 Jan;5(1):16-25 [14735145.001]
  • [Cites] Curr Biol. 2004 Jan 20;14(2):R70-2 [14738753.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):165-72 [14761919.001]
  • [Cites] DNA Seq. 2003 Dec;14(6):436-41 [15018354.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 25;5:18 [15053845.001]
  • [Cites] Rev Clin Exp Hematol. 2003 Dec;7(4):336-61 [15129647.001]
  • [Cites] EMBO Rep. 2004 Jun;5(6):626-31 [15133482.001]
  • [Cites] J Cell Sci. 2004 Jun 15;117(Pt 14):3011-20 [15173315.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3557-61 [9808547.001]
  • [Cites] J Virol. 1999 Feb;73(2):1271-7 [9882331.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):11-9 [9887095.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):1-13 [9973953.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1999;9(1):19-32 [10200909.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):758-63 [10354142.001]
  • [Cites] Oncogene. 1999 Jul 22;18(29):4254-61 [10435638.001]
  • [Cites] Mol Cell. 1999 Jul;4(1):21-33 [10445024.001]
  • [Cites] Mol Microbiol. 1999 Sep;33(5):904-18 [10476026.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):49542-50 [15355977.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54590-8 [15485811.001]
  • [Cites] Mol Cell Biol. 2005 Jan;25(2):563-74 [15632059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):63-8 [15623561.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):195-201 [15665856.001]
  • [Cites] Hum Mol Genet. 2005 Mar 15;14(6):813-25 [15703196.001]
  • [Cites] Cell Res. 2005 Mar;15(3):143-9 [15780175.001]
  • [Cites] J Cell Biol. 2005 Apr 11;169(1):49-60 [15824131.001]
  • [Cites] Mol Cell Biol. 2005 May;25(9):3553-62 [15831461.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4683-9 [15930286.001]
  • [Cites] Retrovirology. 2004;1:20 [15310405.001]
  • [Cites] J Virol. 1999 Dec;73(12):9917-27 [10559304.001]
  • [Cites] Methods. 1999 Nov;19(3):425-33 [10579938.001]
  • [Cites] Mol Cell Biol. 2000 Jan;20(1):26-33 [10594005.001]
  • [Cites] J Cell Biol. 2000 Feb 7;148(3):405-16 [10662768.001]
  • [Cites] Oncogene. 2000 Mar 2;19(10):1257-65 [10713667.001]
  • [Cites] Genetics. 2000 Apr;154(4):1509-21 [10747049.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3554-9 [12824364.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3511-6 [12839935.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2793-808 [12857865.001]
  • [Cites] Retrovirology. 2005;2:45 [16014171.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7071-80 [16103054.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5938-51 [16155601.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Plant Physiol. 2005 Sep;139(1):316-28 [16126853.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Stem Cells. 2005 Nov-Dec;23(10):1634-42 [16099994.001]
  • [Cites] Genome Res. 2005 Dec;15(12):1729-40 [16339371.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):438-47 [16158050.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W191-4 [15215378.001]
  • [Cites] Oncogene. 2004 Jun 24;23(29):4966-74 [15107832.001]
  • [Cites] Mol Biol Cell. 2004 Jul;15(7):3366-78 [15090617.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):31991-4 [15090550.001]
  • [Cites] Cell Cycle. 2004 Apr;3(4):422-4 [15004522.001]
  • [Cites] Mol Cell Biol. 2004 Oct;24(20):8938-50 [15456868.001]
  • [Cites] J Virol. 2004 Nov;78(21):11686-95 [15479810.001]
  • [Cites] Cell Immunol. 1983 Jul 1;79(1):68-80 [6574822.001]
  • [Cites] Jpn J Clin Oncol. 1983;13 Suppl 2:209-14 [6603529.001]
  • [Cites] Blood. 1985 Jul;66(1):120-7 [2988665.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(15):5512-6 [3526331.001]
  • (PMID = 16822311.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI44357; United States / NIAID NIH HHS / AI / R01 AI043894; United States / PHS HHS / / 13969; United States / NIAID NIH HHS / AI / AI43894; United States / NIAID NIH HHS / AI / R29 AI044357
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CREB1 protein, human; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Gene Products, tax; EC 2.7.7.- / DNA Polymerase II
  • [Other-IDs] NLM/ PMC1553470
  •  go-up   go-down


35. Hiromura M, Suizu F, Narita M, Kinowaki K, Noguchi M: Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element. J Biol Chem; 2006 Sep 22;281(38):27753-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The serine/threonine kinase, Akt (protein kinase B) plays a central role in the regulation of intracellular cell survival.
  • Recently, we demonstrated that the proto-oncogene TCL1, overexpressed in human T-cell prolymphocytic leukemia, is an Akt kinase co-activator.
  • Nur77/NGFI-B, an orphan receptor superfamily transcription factor implicated in T-cell apoptosis, is a substrate for Akt.
  • In an electrophoretic mobility shift assay with chromosomal immunoprecipitation assays, wild-type Nur77, but not S350A mutant Nur77, could specifically bind to TCL1-NBRE.
  • To the best of our knowledge, TCL1-NBRE is the first direct target of Nur77 involving the regulation of intracellular cell death survival.

  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16835233.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / NR4A1 protein, human; 0 / Nr4a1 protein, mouse; 0 / Nr4a1 protein, rat; 0 / Nuclear Receptor Subfamily 4, Group A, Member 1; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Receptors, Steroid; 0 / TCL1A protein, human; 0 / Transcription Factors; 9061-61-4 / Nerve Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


36. Maljaei SH, Asvadi-E-Kermani I, Eivazi-E-Ziaei J, Nikanfar A, Vaez J: Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders. Indian J Med Sci; 2005 May;59(5):187-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of CD45 density in the diagnosis of B-cell chronic lymphoproliferative disorders.
  • BACKGROUND: Although many B-cell chronic lymphoproliferative disorders (BCLPDs) including B-cell chronic lymphocytic leukemia (B-CLL) have characteristic clinical and biological features, the overlapping morphologic and immunophenotypic profiles of various BCLPDs, is still the main problem.
  • MATERIALS AND METHODS: The expression of CD45 in 37 patients with BCLPD including typical B-CLL (Group I), atypical B-CLL and CLL/PLL (II), and hairy cell leukemia (HCL), B-prolymphocytic leukemia (B-PLL), and B-non Hodgkin's lymphoma (B-NHL) as non-CLL BCLPDs (III) and in eight healthy age matched controls (IV) was quantitatively compared by flow cytometric CD45/RALS gating strategy.
  • [MeSH-major] Antigens, CD45 / immunology. Leukemia, B-Cell / diagnosis. Membrane Proteins / biosynthesis. Phosphoproteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. B-Lymphocytes / immunology. B-Lymphocytes / metabolism. Biomarkers / blood. Diagnosis, Differential. Female. Flow Cytometry. Fluorescent Antibody Technique, Direct. Follow-Up Studies. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15985726.001).
  • [ISSN] 0019-5359
  • [Journal-full-title] Indian journal of medical sciences
  • [ISO-abbreviation] Indian J Med Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PTPRCAP protein, human; 0 / Phosphoproteins; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


37. Del Giudice I, Osuji N, Dexter T, Brito-Babapulle V, Parry-Jones N, Chiaretti S, Messina M, Morgan G, Catovsky D, Matutes E: B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures. Leukemia; 2009 Nov;23(11):2160-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Prolymphocytic, B-Cell / genetics


38. Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C: A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia. Ann Hematol; 2009 Jan;88(1):85-8
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.
  • [MeSH-major] Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols. Leukemia, Prolymphocytic, B-Cell / drug therapy. Mitoxantrone. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654781.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


39. Pamuk GE, Puyan FO, Unlü E, Oztürk E, Demir M: The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication. Leuk Res; 2009 Jun;33(6):864-7
Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first case of de novo B-cell prolymphocytic leukemia with central nervous system involvement: description of an unreported complication.
  • [MeSH-major] Central Nervous System Diseases / complications. Leukemia, B-Cell / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929411.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


40. Chaar BT, Petruska PJ: Complete response to alemtuzumab in a patient with B prolymphocytic leukemia. Am J Hematol; 2007 May;82(5):417
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Prolymphocytic / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. B-Lymphocytes / pathology. Combined Modality Therapy. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Remission Induction. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160995.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


41. Shimizu D, Nomura K, Matsumoto Y, Nishida K, Taki T, Horiike S, Inaba T, Fujita N, Taniwaki M: Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation. Leuk Lymphoma; 2006 Jun;47(6):1170-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell variant type of T-prolymphocytic leukemia with a four-year indolent course preceding acute exacerbation.
  • [MeSH-major] Leukemia, Prolymphocytic / diagnosis. Leukemia, T-Cell / diagnosis
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / metabolism. CD8-Positive T-Lymphocytes / immunology. Fatal Outcome. Female. Humans. Immunophenotyping. Lymphocytes / metabolism. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840216.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


42. Castagna L, Sarina B, Todisco E, Mazza R, Santoro A: Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant; 2005 Jun;35(12):1225
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up.
  • [MeSH-major] Peripheral Blood Stem Cell Transplantation / adverse effects. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Autoimmune Diseases / etiology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Salvage Therapy. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - B Cell Prolymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down






Advertisement